NASDAQ:EDGE Edge Therapeutics (EDGE) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free EDGE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.74▼$3.9650-Day Range$0.50▼$6.7152-Week Range$0.28▼$17.38Volume423,205 shsAverage Volume373,201 shsMarket Capitalization$120.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media Get Edge Therapeutics alerts: Email Address Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Edge Therapeutics Stock (NASDAQ:EDGE)PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.Read More Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report EDGE Stock News HeadlinesMay 3, 2024 | markets.businessinsider.comOptimistic Buy Rating for Dyne Therapeutics Backed by Promising DYNE-101 Drug Efficacy DataMay 2, 2024 | uk.finance.yahoo.comCorcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...May 4, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” May 2, 2024 | finanznachrichten.de500Newswire, LLC: CB Therapeutics Unveils Revolutionary Breakthroughs in Crafting Pharmaceutical-Grade Cannabinoids and AnaloguesMay 2, 2024 | finance.yahoo.comCB Therapeutics Unveils Revolutionary Breakthroughs in Crafting Pharmaceutical-Grade Cannabinoids and AnaloguesMay 2, 2024 | finance.yahoo.comKelonia Therapeutics to Participate in Upcoming Scientific ConferencesApril 30, 2024 | finance.yahoo.comAsimov Achieves 10x Improvement in Lentiviral Production, Launches New Stable Cell Line Development ServiceApril 29, 2024 | finanznachrichten.deEVOX THERAPEUTICS LIMITED: Evox Therapeutics Names Co-Founder Dr. Per Lundin as Chief Executive OfficerMay 4, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” April 29, 2024 | markets.businessinsider.comEvox Therapeutics Names Co-Founder Dr. Per Lundin as Chief Executive OfficerApril 26, 2024 | finance.yahoo.comRactigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBCApril 26, 2024 | msn.comMundipharma to acquire rezafungin assets from Cidara TherapeuticsApril 26, 2024 | msn.comFDA approves Utility Therapeutics’ Pivya tablets for UTIsApril 25, 2024 | finance.yahoo.comBiologic Therapeutics Drugs Market Size Projections Exhibit a CAGR of 12.2%%, Likely to Attain a Value of USD 1485.0 Billion by 2033April 24, 2024 | markets.businessinsider.comCutting-edge RM6 Million Laboratory Opens at UMMC to Advance Cancer TreatmentApril 23, 2024 | finance.yahoo.comRed Arrow Therapeutics Inc. closes $4.5M Seed Extension roundApril 22, 2024 | uk.finance.yahoo.comVect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to Organs and TumorsApril 22, 2024 | markets.businessinsider.comIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseasesApril 19, 2024 | finance.yahoo.comPeptide Therapeutics Market Projected to Reach $57.97 billion by 2030 - Exclusive Report by 360iResearchApril 18, 2024 | markets.businessinsider.comMaintaining the Edge: Argenx’s Hold Rating Amidst Rising Competition and Promising Therapy ResultsApril 18, 2024 | finance.yahoo.comPanasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing TechnologyApril 15, 2024 | finance.yahoo.comMyeloid Therapeutics to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitApril 15, 2024 | finance.yahoo.comGastrointestinal Therapeutics and Diagnostics: Propelling Global Markets with Cutting-Edge Technologies by BCC Research LLCApril 14, 2024 | msn.comHow cutting-edge therapies—like Ozempic—are changing the drug-pricing landscapeApril 11, 2024 | msn.comPrelude Therapeutics Unveils Promising Cancer Treatment Advances at AACR MeetingApril 4, 2024 | seekingalpha.comBuy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia ManagementApril 4, 2024 | finance.yahoo.comMyeloid Therapeutics to Showcase In Vivo CAR Data and its Diverse mRNA Platform at AACRSee More Headlines Receive EDGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edge Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2018Today5/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EDGE CUSIPN/A CIK1472091 Webwww.edgetherapeutics.com Phone(800) 208-3343FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.29% Return on Assets-56.92% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio5.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book4.02Miscellaneous Outstanding Shares31,510,000Free FloatN/AMarket Cap$120.37 million OptionableNot Optionable Beta3.65 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesFrank K. Bedu-AddoPresident, Chief Executive Officer & DirectorMichael P. KingChief Financial OfficerLauren WoodChief Medical OfficerGregory L. ConnChief Scientific OfficerJanetta TrochimiukControllerKey CompetitorsRezoluteNASDAQ:RZLTNuvectis PharmaNASDAQ:NVCTCyteir TherapeuticsNASDAQ:CYTTRelmada TherapeuticsNASDAQ:RLMDCytomX TherapeuticsNASDAQ:CTMXView All Competitors EDGE Stock Analysis - Frequently Asked Questions How were Edge Therapeutics' earnings last quarter? Edge Therapeutics, Inc. (NASDAQ:EDGE) posted its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.16. What other stocks do shareholders of Edge Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edge Therapeutics investors own include ContraFect (CFRX), Amicus Therapeutics (FOLD), McEwen Mining (MUX), Cerecor (CERC), Synergy Pharmaceuticals (SGYP), Arena Pharmaceuticals (ARNA), BioLineRx (BLRX), Corbus Pharmaceuticals (CRBP), CRISPR Therapeutics (CRSP) and Fate Therapeutics (FATE). This page (NASDAQ:EDGE) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGold ManiaStansberry ResearchThe Gold Grab of the CenturyColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
